- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01203800
Evaluation of Blood Brain Barrier Permeability in Chronic Stroke
Studieoversikt
Status
Detaljert beskrivelse
Evaluation of Blood Brain Barrier Permeability in Chronic Stroke
Mordechai Lorberboym, M.D.1, Yair Lampl, M.D.2, Ronit Gilad, M.D.2.
From the Department of Nuclear Medicine1 and the department of Neurology2 of the Edith Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Introduction
The blood brain barrier (BBB) is a highly selective barrier of brain microvascular endothelial cells that shields the brain from toxic substances in the blood, supplies brain tissues with nutrients, and filters harmful compounds from the brain back to the bloodstream (1). Transport across the BBB is strictly limited through both physical (tight junctions) and metabolic barriers (enzymes, diverse transport systems). BBB breakdown or alterations in transport systems play an important role in the pathogenesis of many CNS diseases (HIV-1 encephalitis, Alzheimer's disease, ischemia, tumors, multiple sclerosis, and Parkinson's disease).
Cerebral ischemia leads to disruption of blood flow, increased BBB permeability, and is associated with rapid depletion of essential nutrients and oxygen (2-3). Only a few studies were designed in humans in order to compare the degree of BBB changes and the neurological outcome after a stroke. The most significant stage of BBB breakdown occurs in humans within 48-72 hours post infarction and is accompanied by increased brain edema volume.
The investigators performed a study on thirty patients with acute stroke of the middle cerebral artery using technetium-99m-DTPA brain SPECT (4). Tc-99m-DTPA (Diethylenetriamine- pentacetic acid) brain scintigraphy is a useful technique for the assessment of BBB disruption. Is has been used in the past to localize areas within the cranium which had been disrupted by infection, neoplasms, trauma or stroke. The study showed that the magnitude of disruption of the BBB was negatively correlated with the change in neurological status with a sensitivity of 95% and a specificity of 89%. Interestingly, a significant proportion of patients with stroke (23%) had no gross evidence of BBB disruption, all of them with very good prognosis.
It is unclear for how long the BBB remains disrupted after a stroke, and whether there is any correlation between the BBB permeability and recurrent ischemic events or delayed functional and neurological outcome after a stroke.
Aim of the study
In this study the investigators intend to explore the long term significance of BBB disruption on the clinical course and the rate of significant recurrent ischemic events in patients with a chronic stroke.
Patients and methods Inclusion criteria
Male and female patients at any age with a history of a large stroke in the territory of the middle cerebral artery, occurring 1-2 years ago or between 2-5 years ago.
Exlusion criteria
Methods:
40 patients will be recruited from the Neurological Outpatient Clinic of the Edith Wolfson Medical Center and from the Neurological Department.
For the SPECT study each patient will receive 740 MBq Tc-99m-DTPA and a SPECT study will be performed 60-90- minutes later. A dual head or a triple head gamma camera is usually used, equipped with high resolution collimators.
References
- Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1:223-236.
- del Zoppo GJ, Hallenbeck JM (2000) Advances in the vascular pathophysiology of ischemic stroke. Thromb Res 98:73-81
- Petty MA, Wettstein JG (2001) Elements of cerebral microvascular ischaemia. Brain Res Rev 36:23-34
- Lorberboym M, Lampl Y, Sadeh M. Correlation of 99mTc-DTPA SPECT of the blood-brain barrier with neurologic outcome after acute stroke. J Nucl Med 2003;44:1898-1904.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Holon, Israel, 58100
- Wolfson medical center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Male and female patients at any age with a history of a large stroke in the territory of the middle cerebral artery, occurring 1-2 years ago or between 2-5 years ago.
Exclusion Criteria:
- Lacunar strokes,
- CNS lesions other than a stroke,
- unable to perform the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Blood Brain Barrier permeability
Tidsramme: 2 years
|
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 0056-09-WOMC
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på A Positive or a Negative Brain SPECT
-
University Hospital, AkershusVestre Viken Hospital Trust; NovartisRekrutteringBrystkreft | Lokalt avansert brystkreft | ER-positiv brystkreft | HER2-negativ brystkreft | Luminal A brystkreft | Luminal B brystkreftNorge
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtTilbakevendende ovariekarsinom | HLA-A*0201 Positive celler tilstede | COL6A3 Positiv | PRAME PositivForente stater
-
Jonsson Comprehensive Cancer CenterCalifornia Institute for Regenerative Medicine (CIRM)AvsluttetSarkom | Ikke-opererbar ondartet neoplasma | Lokalt avansert ondartet neoplasma | HLA-A*0201 Positive celler tilstede | NY-ESO-1 PositivForente stater
-
National Institute of Diabetes and Digestive and...FullførtKronisk hepatitt B e antigen positiv | Kronisk hepatitt B e Antigen negativForente stater
-
Beijing 302 HospitalHar ikke rekruttert ennåHBeAg positiv kronisk hepatitt BKina
-
Dong-A ST Co., Ltd.FullførtHBeAg-positiv kronisk hepatitt BKorea, Republikken
-
Shineway Pharmaceutical Co.,LtdUkjentHBeAg positiv kronisk hepatitt B
-
French National Agency for Research on AIDS and...Gilead Sciences; PharmassetAvsluttetHBe negativ kronisk hepatitt B | Hepatitt B virusinfeksjonFrankrike
-
Gilead SciencesFullførtHBeAg-negativ kronisk hepatitt BHong Kong, Forente stater, Storbritannia, Canada, Australia, Spania, Taiwan, India, Japan, Polen, Romania, Den russiske føderasjonen, Korea, Republikken, Italia, New Zealand, Frankrike, Tyrkia
-
Sun Pharma Advanced Research Company LimitedAktiv, ikke rekrutterendeSunn (for del A) | Kronisk myeloid leukemi (for del B og C)Forente stater, Spania, Ungarn, Italia, India, Belgia, Frankrike, Romania, Singapore, Storbritannia, Korea, Republikken, Tyrkia